For Malignant neoplasm of the kidney, except the renal pelvis.
Indications
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (ADC) following failure of previous sunitinib or cytokine therapy.

Dosage and method of administration
Inlyta treatment should be carried out by a doctor who has experience in anti-cancer therapy. Dosage

The recommended dose of axitinib is 5 mg twice daily.

Treatment should be continued until clinical benefit is observed or until unacceptable toxicity occurs that cannot be treated with concomitant drug therapy or dose adjustment.

If the patient vomits or misses a dose, he should not take an extra dose. The next prescribed dose should be taken at the usual time.

Application method
Axitinib is for oral use. The tablets should be taken orally twice daily at intervals of approximately 12 hours, with or without food (see section 5.2). They should be swallowed whole with a glass of water.
————————————————— ————————————
INLYTA 5 MG FILM COATED TABLETS
L01XE17 • Axitinib
Basic information
MEDICINAL LIST
P2 – PLC Annex 2
RELEASE INFORMATION
RX
PHARMACEUTICAL FORM
FILM COATED TABLETS
MARKETING AUTHORIZATION HOLDER
PFIZER